Regent Pacific Group Ltd
RPG
Company Profile
Business description
Regent Pacific Group Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Its geographical segments are China, Europe, Hong Kong, and Taiwan.
Contact
5 Queen's Road Central
8th Floor, Henley Building
Hong Kong
HKGT: +852 25146111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
17
Stocks News & Analysis
stocks
Moated ASX player’s future growth prospects look solid
We expect the strong earnings momentum at this company to continue, with shares looking fairly valued.
stocks
Ask the analyst: Can this genius product create the next ASX software king?
SiteMinder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,039.80 | 82.70 | -0.91% |
| CAC 40 | 7,849.04 | 30.82 | 0.39% |
| DAX 40 | 23,635.39 | 276.21 | 1.18% |
| Dow JONES (US) | 46,098.30 | 79.98 | 0.17% |
| FTSE 100 | 9,221.20 | 25.54 | 0.28% |
| HKSE | 26,663.80 | 225.29 | 0.85% |
| NASDAQ | 22,506.47 | 245.14 | 1.10% |
| Nikkei 225 | 45,321.95 | 419.68 | 0.93% |
| NZX 50 Index | 13,120.03 | 114.86 | -0.87% |
| S&P 500 | 6,637.49 | 37.14 | 0.56% |
| S&P/ASX 200 | 8,754.80 | 93.70 | -1.06% |
| SSE Composite Index | 3,864.81 | 11.53 | -0.30% |